DexCom Inc [DXCM] - Last Close: $101.25
DexCom is moving higher after a strong earnings release.
The medical device company released its Q3 earnings results after Thursday's close, and the results were better than expected.
DexCom posted Q3 adjusted net income of $0.28 per share and beat analysts' $0.24 EPS forecast.
Revenues of $769.6 million also topped the Street's $751 million target.
DXCM is leading the S&P 500 in today's premarket with a 7.6% gain.
My Take: DXCM has been slowly up-trending since June, but it's expensive with a 213.5 P/E. If it can regain its previous 52-week high, there could be decent upside from here.
HeartCore Enterprise Inc [HTCR] - Last Close: $1.51
HeartCore Enterprises just announced a major licensing deal.
The software developer has signed an agreement with Transcosmos Digital Technology Inc to license its advanced process mining tool, Apromore.
The deal was executed under HeartCore's exclusive right to sell the Apromore platform in Japan.
Financial details of the transaction were not disclosed as of the time of writing.
The news broke on Thursday morning, and it drove HTCR to a 55.6% rally in yesterday's trading session.
HTCR is adding to its Thursday gains with a 25.8% rally on strong volume in today's premarket.
My Take: There weren't a lot of details in the company press release, but the stock is making a dramatic move on the news. Not really sure what to make of this one, so I would advise you approach any potential trades with caution.
Data I/O Corp [DAIO] - Last Close: $3.08
Strong earnings results are boosting shares of Data I/O this morning.
The security device producer reported its Q3 results after Thursday's close, and the release sent shares rocketing upward.
Data I/O reported a surprise Q3 profit of $0.10 per share. Analysts were expecting a $(0.10) per share loss.
The company's quarterly revenues of $7.21 million also beat the consensus estimate of $6.11 million by a wide margin.
DAIO is up 22.7% in today's premarket thanks to the unexpectedly strong Q3 report.
My Take: Data I/O shares are up big on news of the unexpected profit, but this tiny stock is facing stiff resistance at the $4 mark. If it can break through, it has potential to run up to $5 within the next few months if it can keep its momentum going.
Aeglea Bio Therapeutics [AGLE] - Last Close: $0.57
Aeglea Bio is heating up, and The Street is taking notice.
The clinical-stage biotech stock has been on a hot run this week, and it's coming off a 15.1% rally on Thursday.
There hasn't been any clear catalysts to explain the stock's recent run, but it's still getting some love from analysts in today's premarket.
This morning, Wells Fargo and Piper Sandler both announced upgraded ratings on AGLE.
Wells lifted its rating on the stock from "equalweight" to "overweight" and raised its price target to $2 from $1.50.
Piper upgraded the stock to "overweight" from "neutral" and hiked its price target to $1.50 from $1.
The double upgrade is pushing AGLE high in today's premarket. Shares are up 14.7% on active trading volume.
My Take: I don't see any notable good news that could explain AGLE's hot run. That's usually a bad sign, but the Wall Street upgrades make me wonder if there's more to the story. It could be worth keeping an eye on this one.
